Despite these heterogeneous results and the clear need for further investigation, the actual evidence supports the decision of the 13th International Congress on aPL to recommend IgA aβ2GPI testing in SN-APS, as previously mentioned. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.